The potential of dopamine agonists in drug addiction

Expert Opinion on Investigational Drugs
Thomas R KostenTherese A Kosten

Abstract

The use of dopamine agonists in alcohol, stimulant and nicotine dependence has been examined. The direct agonists, such as bromocriptine and pergolide, have not shown utility in alcohol or cocaine abuse and dependence in larger controlled trials. Indirect agents, such as selegiline, may be helpful in cocaine or nicotine abuse and larger clinical trials are underway. Disulfiram may also raise dopamine levels and has shown promise for cocaine dependence. Other indirect agents, such as mazindol and methylphenidate, have not proven effective for cocaine addiction but have not been tested in alcohol or nicotine abuse. Agents for subtypes of dopamine receptors, such as D3, and the use of partial agonists may be useful future treatment approaches. Animal studies also suggest that tailoring treatment to subgroups of patients based on genotype may improve responses.

References

Oct 1, 1992·Drug and Alcohol Dependence·A I AltermanC P O'Brien
Jun 12, 1992·Brain Research·D W Self, L Stein
Jul 1, 1992·Psychiatry Research·C J McDougleH D Kleber
May 1, 1992·Trends in Pharmacological Sciences·G F Koob
Jun 28, 1992·Annals of the New York Academy of Sciences·G F Koob
Dec 1, 1991·Alcoholism, Clinical and Experimental Research·M DongierG Schwartz
Dec 1, 1991·Pharmacology, Biochemistry, and Behavior·K D WardL Landsberg
Oct 1, 1991·The Journal of Nervous and Mental Disease·T A Kosten, T R Kosten
Aug 1, 1989·Pharmacology, Biochemistry, and Behavior·K KumorJ Jaffe
Jan 1, 1989·The American Journal of Drug and Alcohol Abuse·R S SchottenfeldJ H Jaffe
May 5, 1988·The New England Journal of Medicine·F H Gawin, E H Ellinwood
Jan 1, 1984·Psychopharmacology·R J WestB Kadam
Aug 1, 1983·Acta Psychiatrica Scandinavica·V Borg
Feb 1, 1982·Acta Psychiatrica Scandinavica·V Borg, T Weinholdt
Jul 1, 1995·Drug and Alcohol Dependence·K A HabernyG E Bigelow
Oct 1, 1994·Trends in Pharmacological Sciences·L Pulvirenti, G F Koob
Dec 1, 1994·Clinical Pharmacology and Therapeutics·B NickelG Schulze
Jan 1, 1993·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·E H HeinonenM Scheinin
Jan 1, 1993·Journal of General Internal Medicine·H MoscovitzL Nelson
Oct 1, 1995·Drug and Alcohol Dependence·S M StineD S Charney
Nov 1, 1995·The American Journal of Drug and Alcohol Abuse·A MargolinT R Kosten
Feb 22, 1996·Nature·J S FowlerR Cilento
Mar 1, 1996·Pharmacology, Biochemistry, and Behavior·Y K FungY S Lau
Nov 26, 1996·Proceedings of the National Academy of Sciences of the United States of America·J S FowlerA P Wolf
Apr 1, 1997·The American Journal on Addictions·R MalcolmC E Cochrane
Aug 1, 1997·Clinical Pharmacokinetics·I Mahmood
Nov 15, 1997·Psychopharmacology·R D SpealmanS Rosenzweig-Lipson
Dec 31, 1997·Journal of Clinical Psychopharmacology·J GrabowskiA Korszun
Mar 26, 1998·Biological Psychiatry·M B BowersT R Kosten
Aug 26, 1998·Archives of General Psychiatry·S M HallE Triffleman
Oct 27, 1998·Drug and Alcohol Dependence·E F McCance-KatzP Jatlow

❮ Previous
Next ❯

Citations

May 13, 2004·Naunyn-Schmiedeberg's Archives of Pharmacology·Natasa MilivojevicMarko Zivin
Sep 26, 2009·Psychopharmacology·Matthew W FeltensteinRonald E See
Oct 26, 2006·Behavior Genetics·Colin N HaileTherese A Kosten
Nov 26, 2003·Drug and Alcohol Dependence·Charles W SchindlerWinnie L Gee
Dec 24, 2003·Drug Discovery Today·John F CryanAthina Markou
Oct 12, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mark J Williams, Bryon Adinoff
May 2, 2003·The New England Journal of Medicine·Thomas R Kosten, Patrick G O'Connor
Jul 28, 2010·Proceedings of the National Academy of Sciences of the United States of America·Chiang-Shan R LiRobert T Malison
Nov 4, 2011·BMC Medicine·Daryl Shorter, Thomas R Kosten
Sep 29, 2004·Psychopharmacology·Richard De La GarzaAri D Kalechstein
Sep 17, 2013·Expert Opinion on Investigational Drugs·Christopher D VerricoRichard De La Garza
Jun 7, 2005·Expert Opinion on Emerging Drugs·Raye Z LittenMark Egli
May 23, 2009·The American Journal of Drug and Alcohol Abuse·Colin N HaileTherese A Kosten
Sep 27, 2014·Alcoholism, Clinical and Experimental Research·Aqilah M McCaneChristopher C Lapish
Sep 4, 2004·Addictive Behaviors·John GrabowskiS Stevens Negus
Aug 3, 2007·Biochemical Pharmacology·Michael D Köhnke
Jun 30, 2006·Biological Psychiatry·Matthew W FeltensteinRonald E See
Jul 30, 2005·Drug and Alcohol Dependence·David A Gorelick, Jeffery N Wilkins
Apr 17, 2015·Annals of the New York Academy of Sciences·Kalynda K Gonzales, Yoland Smith
Jul 16, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·D ShorterT R Kosten
Apr 16, 2003·Psychopharmacology·Jonathan L Katz, Stephen T Higgins
Jun 27, 2014·Frontiers in Neural Circuits·Kori L BrewerStefan Clemens
Jan 15, 2009·Journal of Clinical Psychopharmacology·Jochen MutschlerFalk Kiefer
May 17, 2006·Journal of Clinical Psychopharmacology·Jesse J SuhCharles P O'Brien
Mar 22, 2006·Addiction·David M FergussonL John Horwood
Nov 27, 2014·Expert Opinion on Emerging Drugs·Daryl ShorterThomas R Kosten

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.